Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasis of the cancer cells. Nimotuzumab is an engineered, intermediate affinity anti-EGFR antibody, that apart from other drugs in its class, is very safe and does not cause hypomagnesemia or grade 3–4 cutan...
Main Authors: | Tania Crombet Ramos, Braulio Mestre Fernández, Zaima Mazorra Herrera, Normando E. Iznaga Escobar |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00817/full |
Similar Items
-
Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study
by: Ashok Kumar, et al.
Published: (2019-01-01) -
Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience
by: Shyamji Rawat, et al.
Published: (2019-01-01) -
Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer
by: K. Satish Srinivas, et al.
Published: (2020-01-01) -
Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence
by: Sundaram Subramanian, et al.
Published: (2018-01-01) -
Humoral characteristics of head and neck tumors in patients treated with nimotuzumab
by: Lisandra Roca Serra, et al.
Published: (2018-05-01)